Delivery Order SPE2DB20D9329-SPE2DB25FZJ41

Award Date 2/7/25
Potential Completion Date 3/3/25
Potential Value $9.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $9,284.40 firm fixed-price contract is for the delivery of Xolair 150 mg/mL syringes to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999 that...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $9,284.40 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/ml syringes, a specialized pharmaceutical product. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC enables the DLA to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $1,547.40 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Xolair 150 mg/ml syringes and is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to issue delivery orders for a wide range of pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract, valued at $7,737.00, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order is part of DMS Pharmaceutical Group's larger, single-award indefinite delivery contract (IDC) with the DLA valued at up to $499,999,999, which runs through December 31, 2025. Under this IDC, the company provides a wide range of pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a $30,948.00 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xolair 150 mg/mL syringes to support the medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $3,094.80 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/mL syringes. This delivery order is placed under a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 between DMS Pharmaceutical Group and the DLA, which covers a wide range of pharmaceutical products including branded and generic prescription drugs,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of Xolair 150 mg/ml syringes and is part of a larger Indefinite Delivery Contract (IDC) worth up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This IDC enables the DLA to issue delivery orders for a...
The U.S. Defense Logistics Agency (DLA) awarded a $7,737.00 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) with DMS Pharmaceutical Group that supports the recurring pharmaceutical supply needs of military health facilities worldwide. Under this contract, DMS Pharmaceutical Group will provide the...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $18,568.80, is for the delivery of Xolair 150 mg/mL syringes to support the medical supply needs of military health facilities. This order is placed under DMS Pharmaceutical Group's larger indefinite-delivery contract (IDC) with the DLA, valued at up to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $11,605.50, is for the supply of Xolair 150 mg/mL syringes to support the medical needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to...
  • SPE2DB20D9329
    Indefinite Delivery Contract
  • SPE2DB20D9329-SPE2DB25FZJ41
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $9,284.40 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Xolair 150 mg/ml syringes to support the medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, which covers a wide range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains. The contract has an ultimate completion date of March 3, 2025.

Generated 5/9/25, 9:51 AM